elitek- rasburicase kit
sanofi-aventis u.s. llc - rasburicase (unii: 08gy9k1euo) (rasburicase - unii:08gy9k1euo) - rasburicase 1.5 mg in 1 ml - elitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. limitations of use elitek is indicated only for a single course of treatment [see warnings and precautions (5.1)] . elitek is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase [see boxed warning, warnings and precautions (5.1, 5.2, 5.3)] . elitek is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (g6pd) [see boxed warning, warnings and precautions (5.2)] . risk summary based on findings in animals, elitek may cause fetal harm when administered to pregnant women. in animal reproduction studies, intravenous administration of rasburicase to pregnant rabbits during organo
fasturtec rasburicase (rys) 1.5mg powder for injection vial with diluent
sanofi-aventis australia pty ltd - rasburicase, quantity: 1.5 mg - injection - excipient ingredients: poloxamer; water for injections - rasburicase is indicated for the treatment and prophylaxis of acute hyperuricaemia, in patients with haematological malignancy at risk of a rapid tumour lysis.
fasturtec rasburicase 7.5mg powder for injection vial with solvent ampoule
sanofi-aventis australia pty ltd - rasburicase -
fasturtec
pharmacy retailing (nz) ltd t/a healthcare logistics - rasburicase 1.5mg - powder for infusion - 1.5 mg - active: rasburicase 1.5mg excipient: alanine dibasic sodium phosphate dihydrate dibasic sodium phosphate dodecahydrate mannitol monobasic sodium phosphate dihydrate poloxamer 188 water for injection - the treatment and prophylaxis of acute hyperuricaemia, in patients with haematological malignancy at risk of a rapid tumour lysis.
fasturtec
sanofi-aventis new zealand limited - rasburicase 7.5mg - powder for infusion - 7.5 mg - active: rasburicase 7.5mg excipient: alanine dibasic sodium phosphate dihydrate dibasic sodium phosphate dodecahydrate mannitol monobasic sodium phosphate poloxamer 188 water for injection - the treatment and prophylaxis of acute hyperuricaemia, in patients with haematological malignancy at risk of a rapid tumour lysis.
fasturtec
sanofi winthrop industrie - rasburicase - hyperuricemia - all other therapeutic products - treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in adults, children and adolescents (aged 0 to 17 years) with haematological malignancy with a high tumour burden and at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy.
fasturtec powder for solution
sanofi-aventis canada inc - rasburicase - powder for solution - 1.5mg - rasburicase 1.5mg - enzymes
fasturtec powder for solution
sanofi-aventis canada inc - rasburicase - powder for solution - 7.5mg - rasburicase 7.5mg - enzymes
fasturtec powder for solution for infusion 1.5 mgvial
sanofi-aventis singapore pte. ltd. - rasburicase - injection, powder, for solution - 1.5 mg/vial - rasburicase 1.5 mg/vial
fasturtec 1.5mg powder and solvent for solution for infusion vials
sanofi - rasburicase - powder and solvent for solution for infusion - 1.5mg